Journal of Neurology and Neurosurgery · 2014 · 16 citations · 33 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor MicroenvironmentCancer ImmunotherapyCytokine-based TherapyGlioblastomaImmunotherapy For Brain TumorsImmunotherapy For Solid TumorsTumor Microenvironment ModulationBlood-brain Barrier ImmunityGlioblastoma Clinical TrialsGlioblastoma ImmunologyGlioblastoma ImmunotherapyGlioblastoma Tumor MicroenvironmentImmunosuppressive MicroenvironmentNegative Co-stimulatory SignalingTargeted Immunotherapy
Glioblastoma is a form of brain tumor with a very high morbidity and mortality. Despite decades of research, the best treatments currently in clinical practice only extend survival by a number of months. A promising alternative to conventional treatment for glioblastomas is immunotherapy. Although proposed over a century ago, the field of cancer immunotherapy has historically struggled to translate it into effective clinical treatments. Better understanding is needed of the various regulatory and co-stimulatory factors in the glioblastoma patient for more efficient immunotherapy treatments. The tumor microenvironment is anatomically shielded from normal immune-surveillance by the blood-brain barrier, irregular lymphatic drainage system, and it's in a potently immunosuppressive environment. Immunotherapy can potentially manipulate these forces effectively to enhance anti-tumor immune response and clinical benefit. New treatments utilizing the immune system show promise in terms of targeting and efficacy. This review article attempts to discuss current practices in glioblastoma treatment, the theory behind immunotherapy, and current research into various clinical trials.
33
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2009 · 2.4K citations
Medicine, Oncology, Pharmacology +17